This study is to assess the prevalence of Asthma COPD Overlap in subjects with diagnosed asthma and chronic obstructive pulmonary disease (COPD). The subsequent morbidity and mortality of subjects will be followed up for 3 years.
Rationale: Around 15 to 20% of COPD patients have features of asthma. These patients have more frequent and more severe exacerbations, and higher medical utilization. The Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have given joint recommendations on the identification, diagnosis and treatment of these patients having Asthma-COPD Overlap (ACO). These are at present expert opinions and further studies are needed to establish the optimal definitions and treatment options. The recommendations proposed by the guidelines have been adapted for use in the Asia area countries. Nonetheless, the application to clinical practice has not been well established and there are no prevalence data available on the COPD with asthma symptom population or asthma with COPD symptoms population based on the recommended features for identification. This is the current data gap in Asia. Primary objective: To determine the proportion and clinical characteristics of patients with ACO as defined by the joint GINA and GOLD recommendation amongst diagnosed COPD and asthma patients seen at the out-patient clinics
Study Type
OBSERVATIONAL
Enrollment
1,600
No intervention
Prince of Wales Hospital
Hong Kong, Hong Kong
RECRUITINGPercentage of prevalence of Asthma COPD overlap among the asthma and COPD subjects.
To determine the proportion and clinical characteristics of patients with ACO as defined by the joint GINA and GOLD recommendation amongst diagnosed COPD and asthma patients seen at the out-patient clinics. (Assessment: % of subjects with ACO among patients with asthma and COPD respectively)
Time frame: 3 years
Percentage of patient with treatment that is different from the guidelines recommendation
To evaluate the gap between guideline recommendations and real-world clinical practice in identifying COPD patients with asthma and asthma patients with COPD
Time frame: 3 years
The percentages of patients on various medications (e.g. inhaled steroid, LABA, LAMA)
To review the medications given to COPD patients with asthma and asthma patients with COPD compared to guideline recommendations
Time frame: 3 years
The pecentages of patients receiving different symptoms control assessments (e.g. use of Asthma control test, use of COPD assessment test)
To review the current practices of symptom control assessment
Time frame: 3 years
Percentages of subjects with morbidity (e.g. congestive heart failure)
To assess the 3 year morbidity of ACO patient compared to COPD and asthma patients.
Time frame: 3 years
Percentages of subjects with mortality
To assess the 3 year mortality of ACO patient compared to COPD and asthma
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Percentages of patients with various Genetic markers
Genetic markers got differentiating ACO patients from patients with COPD or asthma
Time frame: 3 years